Plan B distributor not optimistic about approval

05/5/2004 | Washington Post, The

The president of Barr Laboratories' research division said she does not expect the FDA to switch the controversial morning-after contraceptive from prescription to over-the-counter status because of a lack of communication with the government agency. She said the drug company is still hopeful the agency, whose advisory committee overwhelmingly voted for the switch, would grant an "approvable letter" to allow Barr to make the switch in the future once certain conditions are met.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT